Scleroderma, Systemic
12 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| AdMSC for scleroderma, systemic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| anti-CD19 CAR-T cells for scleroderma, systemic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD0120 for scleroderma, systemic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belimumab for scleroderma, diffuse | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CAR-T cells targeting CD19 for scleroderma, systemic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclophosphamide + FLUDARABINE + Prulacabtagene Leucel for scleroderma, systemic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MTX-474 for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| QEL-005 for scleroderma, diffuse | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rituximab + belimumab for scleroderma, systemic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telitacicept for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tulisokibart for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |